Core Viewpoint - Watson Bio (300142) will disclose its Q3 2025 report by the end of this month, as per regulations, and investors are encouraged to stay tuned for updates [1] Company Information - Watson Bio is set to release its Q3 2025 financial report by the end of October 2023 [1]

Core Viewpoint - Watson Bio (300142) emphasizes its commitment to comply with shareholder information disclosure regulations and aims to build a self-sufficient vaccine industry in China while supplying high-quality products to the global market [1] Group 1: Company Strategy - The company is increasing resource investment across various areas including talent development, project introduction, market marketing, international product registration, clinical trials, international certification, and cooperative production to diversify its international business [1] - Watson Bio is exploring new cooperation models based on its extensive experience to deepen and broaden overseas collaborations, aiming to make innovative vaccines accessible to more people [1] Group 2: Market Positioning - The company aims to enhance its influence in the international market and contribute to global vaccine accessibility [1] - Investors are encouraged to follow the company's announcements for updates on product exports and overseas collaborations [1]

Core Viewpoint - Watson Bio emphasizes the broad application prospects of mRNA technology, highlighting its advantages such as shorter R&D cycles, rapid iteration, and high efficacy [1] Company Developments - The company has been actively developing mRNA vaccines in collaboration with partners, gradually building and solidifying its mRNA vaccine technology platform over the past few years [1] - Recently, Watson Bio submitted clinical trial applications for respiratory syncytial virus mRNA vaccine and lyophilized varicella-zoster virus mRNA vaccine to the National Medical Products Administration, which has accepted these applications [1] Investment and Financial Impact - Watson Bio holds shares in Hong Kong-listed companies Saint No Pharmaceutical and Jiahe Biotech, with the impact on its net profit and related indicators being influenced by the stock price fluctuations of these companies [1]

证券日报网讯 沃森生物10月17日在互动平台回答投资者提问时表示，公司持续关注二级市场情况，将 结合自身发展和政策、市场情况，依法合规地寻求切实可行的市值管理方式提升公司的投资价值。公司 严格遵守上市公司规范运作的相关法律法规和规范性文件的规定，后续如有相关安排会履行有关法定程 序并及时进行公告。 （编辑 王雪儿） ...

Core Viewpoint - Watson Bio's stock has shown fluctuations with a recent increase of 2.02%, but the year-to-date performance indicates a decline of 3.73% [1] Financial Performance - For the first half of 2025, Watson Bio reported revenue of 1.154 billion yuan, a year-on-year decrease of 19.47% [2] - The net profit attributable to shareholders for the same period was 43.16 million yuan, down 74.69% year-on-year [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 117,300, a rise of 3.73% from the previous period [2] - The average number of circulating shares per shareholder decreased by 3.88% to 13,268 shares [2] Dividend Distribution - Since its A-share listing, Watson Bio has distributed a total of 403 million yuan in dividends, with 47.98 million yuan distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, the largest circulating shareholder is E Fund's ChiNext ETF, holding 40.27 million shares, a decrease of 1.0618 million shares from the previous period [3] - The third-largest shareholder is the China National Bio-Medical Index A, holding 26.98 million shares, down by 2.1952 million shares [3] - The fifth-largest shareholder is the Southern CSI 500 ETF, which increased its holdings by 3.1893 million shares to 23.81 million shares [3]

证券代码：300142 证券简称：沃森生物 公告编号：2025-056 云南沃森生物技术股份有限公司 关于公司第五届董事会延期换届的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 在完成换届之前，公司第五届董事会、监事会全体成员、董事会各专门委员 会委员及公司高级管理人员将依照《中华人民共和国公司法》《中华人民共和国 证券法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等相关法律法规、部门规章、规 范性文件和《公司章程》的规定继续履行职责和义务。 公司董事会延期换届不会对公司正常生产经营产生影响。公司将尽快完成 《公司章程》的修订并履行换届选举程序，积极推进换届工作，并按照相关规定 及时履行信息披露义务。 特此公告。 云南沃森生物技术股份有限公司 董事会 二〇二五年十月十四日 云南沃森生物技术股份有限公司（以下简称"公司"）第五届董事会、监事 会于 2025 年 10 月 12 日任期届满。鉴于公司新一届董事会的换届工作尚在筹备 中，同时，根据新修订的《中华人民共和国公司法》《上市 ...

Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]

Core Viewpoint - Watson Bio has made significant progress in its strategic layout in the Middle East by obtaining a drug registration certificate for its 13-valent pneumococcal polysaccharide conjugate vaccine from the Jordan Food and Drug Administration [1] Group 1 - The vaccine produced by Watson Bio's subsidiary, Yuxi Watson Bio Technology Co., Ltd., has received the drug registration certificate in Jordan [1] - This marks an important breakthrough in the internationalization process of Watson Bio's 13-valent pneumococcal polysaccharide conjugate vaccine [1] - The actual market launch time and sales performance of the vaccine in Jordan remain uncertain [1]

Core Viewpoint - Watson Bio (300142.SZ) announced that its subsidiary, Yuxi Watson Biotechnology Co., Ltd., has received a drug registration certificate from the Jordan Food & Drug Administration for its 13-valent pneumococcal polysaccharide conjugate vaccine [1] Group 1: Product Information - The 13-valent pneumococcal polysaccharide conjugate vaccine is primarily intended for infants and children aged 6 weeks to under 5 years [1] - The vaccine is designed to prevent infections caused by 13 serotypes of pneumococcus included in the vaccine: types 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F [1] - This vaccine was approved for sale in China in 2020 [1]

Core Viewpoint - Watson Bio (300142.SZ) announced that its subsidiary, Yuxi Watson Biotechnology Co., Ltd., has received a Drug Registration Certificate from the Jordan Food & Drug Administration for its 13-valent pneumococcal polysaccharide conjugate vaccine [1] Group 1: Product Information - The 13-valent pneumococcal polysaccharide conjugate vaccine is primarily intended for infants and children aged 6 weeks to under 5 years [1] - The vaccine is designed to prevent infections caused by 13 serotypes of pneumococcus included in the vaccine: types 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F [1] - This vaccine was approved for sale in China in 2020 [1]